Highly active antiretroviral therapy — Competitive Intelligence Brief

Highly active antiretroviral therapy (Highly active antiretroviral therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy. Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition) Infectious Disease / Virology Small molecule

Target snapshot

Highly active antiretroviral therapy (Highly active antiretroviral therapy) — PETHEMA Foundation. HAART uses a combination of antiretroviral drugs from different classes to suppress HIV replication by targeting multiple steps of the viral lifecycle simultaneously.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Highly active antiretroviral therapy TARGET	Highly active antiretroviral therapy	PETHEMA Foundation	marketed	Antiretroviral combination therapy	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen composition)
Atazanavir + Ritonavir + 2 NRTIs	Atazanavir + Ritonavir + 2 NRTIs	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, cytochrome P450 (CYP3A4)
CAR	CAR	ViiV Healthcare	marketed	Antiretroviral combination therapy (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase
AZT+3TC+IDV+RTV	AZT+3TC+IDV+RTV	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease
Switch to DRV/cobicistat + 3TC	Switch to DRV/cobicistat + 3TC	Hospitales Universitarios Virgen del Rocío	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitor)	HIV protease, CYP3A4, HIV reverse transcriptase
Reyataz + Norvir + Truvada	Reyataz + Norvir + Truvada	ViiV Healthcare	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
didanosine + lamivudine + efavirenz	didanosine + lamivudine + efavirenz	Clinical Trial Agency of HIV Study Group	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy class)

1. ANRS, Emerging Infectious Diseases · 1 drug in this class
2. Chang Gung Memorial Hospital · 1 drug in this class
3. Danish HIV Research Group · 1 drug in this class
4. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
5. Hospital Nossa Senhora da Conceicao · 1 drug in this class
6. Kristine Patterson, MD · 1 drug in this class
7. PETHEMA Foundation · 1 drug in this class
8. University of Alberta · 1 drug in this class
9. University of North Carolina, Chapel Hill · 1 drug in this class